Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer
Author
Bulumulle, Anushi; Brody, Heather; Macherla, Shravanti; Walker, Paul R.; Sehgal, Kartik; Gill, Ritu R.; Qilleri, Aleksandra; McDonald, Danielle C.; Cherry, Cynthia R.; Shea, Meghan; Huberman, Mark S.; VanderLaan, Paul A.; Weiss, Glen J.; Costa, Daniel B.; Rangachari, Deepa
Date
2021
Citation:
APA:
Bulumulle, Anushi, & Brody, Heather, & Macherla, Shravanti, & Walker, Paul R., & Sehgal, Kartik, & Gill, Ritu R., & Qilleri, Aleksandra, & McDonald, Danielle C., & Cherry, Cynthia R., & Shea, Meghan, & Huberman, Mark S., & VanderLaan, Paul A., & Weiss, Glen J., & Costa, Daniel B., & Rangachari, Deepa. (January 2021).
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer.
,
(),
-
. Retrieved from
http://hdl.handle.net/10342/11327
MLA:
Bulumulle, Anushi, and Brody, Heather, and Macherla, Shravanti, and Walker, Paul R., and Sehgal, Kartik, and Gill, Ritu R., and Qilleri, Aleksandra, and McDonald, Danielle C., and Cherry, Cynthia R., and Shea, Meghan, and Huberman, Mark S., and VanderLaan, Paul A., and Weiss, Glen J., and Costa, Daniel B., and Rangachari, Deepa.
"Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer". .
. (),
January 2021.
September 26, 2023.
http://hdl.handle.net/10342/11327.
Chicago:
Bulumulle, Anushi and Brody, Heather and Macherla, Shravanti and Walker, Paul R. and Sehgal, Kartik and Gill, Ritu R. and Qilleri, Aleksandra and McDonald, Danielle C. and Cherry, Cynthia R. and Shea, Meghan and Huberman, Mark S. and VanderLaan, Paul A. and Weiss, Glen J. and Costa, Daniel B. and Rangachari, Deepa,
"Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer," , no.
(January 2021),
http://hdl.handle.net/10342/11327 (accessed
September 26, 2023).
AMA:
Bulumulle, Anushi, Brody, Heather, Macherla, Shravanti, Walker, Paul R., Sehgal, Kartik, Gill, Ritu R., Qilleri, Aleksandra, McDonald, Danielle C., Cherry, Cynthia R., Shea, Meghan, Huberman, Mark S., VanderLaan, Paul A., Weiss, Glen J., Costa, Daniel B., Rangachari, Deepa.
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer. .
January 2021;
():
.
http://hdl.handle.net/10342/11327. Accessed
September 26, 2023.
Collections